CEO Executive AssistantPharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects of pharmaceutical products. It is a legally mandated, technically complex function that pharmaceutical companies must execute flawlessly to maintain product approvals and protect patients.
For pharma CEOs, pharmacovigilance operations represent one of the most important and most thoroughly delegable functions in the organization. This guide covers the specific operational delegation model for a mature pharmacovigilance program.
Understanding CEO Accountability in Pharmacovigilance
The pharmaceutical CEO is the individual ultimately responsible to regulatory authorities for the company’s pharmacovigilance obligations. In many jurisdictions, regulations explicitly assign responsibility for PV quality to senior management.
But accountability does not require operational management. The CEO who understands PV accountability without becoming a PV operator builds a better pharmacovigilance program than one who tries to manage signal detection personally.
The CEO’s PV role:
Ensuring adequate PV resources. Regulatory agencies scrutinize whether companies have appropriately staffed and resourced their PV functions. The CEO must champion PV investment, particularly in periods of budget pressure.
QPPV or equivalent relationship. In Europe, the Qualified Person for Pharmacovigilance has defined legal responsibilities. The CEO’s relationship with the QPPV ensures that this critical function has organizational standing and support.
Accountability for PV quality systems. When PV inspections occur or compliance failures arise, the CEO is responsible for organizational response.
Patient safety culture. The CEO models the organizational priority of patient safety over commercial convenience.
Operational Delegation Map for Pharmacovigilance
Case Processing Operations
Who owns it: PV Operations team, case processing coordinators
What they manage:
- Intake and triage of adverse event reports from all sources
- Medical coding of adverse event terms using MedDRA coding
- Case narrative writing and quality review
- Data entry into the safety database
- Expedited reporting to regulatory authorities (15-day reports)
- Periodic regulatory reporting including PSURs, PBRERs, and PADERs
CEO interaction: None with routine case processing. The CEO receives summary volume and compliance metrics.
Signal Detection and Evaluation
Who owns it: Signal management team, PV scientists, medical officers
What they manage:
- Quantitative signal detection using disproportionality analysis
- Qualitative signal evaluation and case series review
- Literature signal identification and assessment
- Regulatory authority signal queries and responses
- Signal management committee facilitation and documentation
CEO interaction: Briefed on significant signals that may require regulatory action or have commercial implications.
Risk Management Plan and REMS Management
Who owns it: Risk management team, regulatory affairs, medical affairs
What they manage:
- RMP updates and regulatory submissions
- REMS program administration including prescriber enrollment and patient registration
- Additional risk minimization measure design and implementation
- Effectiveness evaluation of risk minimization measures
CEO interaction: Approves major RMP commitments. Receives quarterly REMS compliance status.
PV Agreements with Partners
Who owns it: PV operations, legal, business development
What they manage:
- Pharmacovigilance Agreements with marketing authorization partners, distributors, and licensees
- Safety data exchange protocols
- Partner PV compliance oversight and partner audit programs
CEO interaction: Approves template PV agreement terms. Informed of material partner compliance failures.
PV Quality System
Who owns it: PV quality, broader quality organization
What they manage:
- PV SOP development and maintenance
- PV training program for all staff
- Internal PV audit program and regulatory inspection preparation
- PV metrics and CAPA management
CEO interaction: Reviews PV quality metrics quarterly. Informed of significant compliance findings.
Governance Infrastructure for PV Delegation
Safety Management Team
A cross-functional Safety Management Team, including representatives from PV, medical affairs, regulatory affairs, and commercial, reviews significant safety topics, coordinates responses to safety signals, and makes recommendations on safety actions. The QPPV or Chief Safety Officer chairs this team.
Monthly PV Operations Report
A monthly PV operations report from the head of pharmacovigilance to the CEO covers:
- Case volume and processing compliance on-time reporting rates
- Active signal evaluations and their status
- Regulatory authority communications about safety
- REMS compliance status
- Significant partner PV issues
- PV budget versus plan
This report gives the CEO complete PV operational visibility in a brief review.
Annual PV System Audit
An annual pharmacovigilance system audit, conducted by the quality team or external auditors, provides an independent assessment of PV system effectiveness. The CEO reviews the audit summary and approves the management response to significant findings.
For pharma CEOs managing pharmacovigilance alongside post-market surveillance and quality, pharma CEO post-market surveillance covers the closely related post-market surveillance delegation framework.
The broader regulatory and quality delegation context is addressed in delegation guide for pharma CEO: regulatory affairs.
Resourcing Pharmacovigilance for Effective Delegation
The most common reason pharmacovigilance delegation fails is inadequate resourcing. PV functions that are chronically understaffed relative to case volume accumulate compliance backlogs that eventually produce regulatory action.
Industry benchmarks suggest approximately one FTE per 400 to 600 cases annually for case processing operations, though this varies significantly based on product type, indication, and geographic reporting requirements. The CEO should ensure that PV headcount planning reflects actual case volume rather than budget optimization.
Where internal PV capacity is insufficient, outsourcing case processing to a specialized PV service provider is an appropriate and widely used model. Managing the outsourcing relationship is a PV operations function; selecting and contracting with the service provider involves the CEO at the strategic decision level.
Conclusion
Pharmacovigilance is a specialized, regulated, and critically important function that must be thoroughly delegated to expert staff while remaining a CEO-level accountability. The pharma CEO who funds the PV function adequately, builds strong PV leadership, establishes rigorous governance, and maintains visibility through regular reporting fulfills their accountability obligations without becoming a PV operator.
Resource it. Govern it. Stay accountable for it.
For pharmaceutical pharmacovigilance regulatory requirements and operational standards, visit McKinsey.com/industries/life-sciences.
Related Reading
For further context, explore Pharma CEO Delegation for Drug Pipeline Management and Pharma CEO Delegation for Launch Teams.